•
Jun 30, 2022

NeueHealth Q2 2022 Earnings Report

Reported strong performance due to progress in reducing medical costs, accurate risk adjustment capture, and improving operational performance.

Key Takeaways

Bright Health Group reported a revenue of $1.6 billion, up 41.5% from Q2'21. The GAAP Net Loss was $251.3 million, and the Adjusted EBITDA Loss was $194.9 million. The Enterprise Medical Cost Ratio was 88.8%. The company reaffirmed its 2022 Consolidated Revenue, MCR, and Adjusted EBITDA guidance.

Revenue of $1.6 billion, up 41.5% from Q2'21.

GAAP Net Loss of $251.3 million.

Adjusted EBITDA Loss of $194.9 million.

Enterprise Medical Cost Ratio of 88.8%.

Total Revenue
$1.58B
Previous year: $1.11B
+41.6%
EPS
-$36
Previous year: -$22.4
+60.7%
Medical Cost Ratio
88.8%
Previous year: 86.8%
+2.3%
Operating Cost Ratio
26.2%
Previous year: 23.4%
+12.0%
Gross Profit
$149M
Previous year: $415M
-64.0%
Cash and Equivalents
$1.43B
Previous year: $1.51B
-5.2%
Free Cash Flow
$232M
Previous year: $147M
+57.8%
Total Assets
$5.26B
Previous year: $3.6B
+46.1%

NeueHealth

NeueHealth

NeueHealth Revenue by Segment

Forward Guidance

Bright Health Group expects a total revenue of $6.8 billion to $7.1 billion with an expected enterprise Medical Cost Ratio between 90% and 94%. Bright HealthCare end-of-year membership is expected to be approximately 1,000,000, while NeueHealth Revenue is expected to be approximately $2.2 billion. Adjusted EBITDA for 2022 is expected to be a loss of between $500.0 million and $800.0 million

Revenue & Expenses

Visualization of income flow from segment revenue to net income